Drug intelligence / Profile preview

SBRX15

Development stage: Preclinical
Lead developer: Stramsen Biotech
Modality: Small Molecules

Overview

SBRX15 is a plant-based drug candidate developed by Stramsen Biotech for the treatment of urogenital tract infections. It is designed to control a broad range of pathogens, including bacteria, viruses, protozoa, and fungi within the urogenital tract. The drug is part of Stramsen's pipeline of botanical therapeutics derived from a proprietary database of medicinal plants. While Stramsen Biotech has multiple candidates in early-stage clinical trials, the specific development phase for SBRX15 is not publicly specified, though it remains an active part of their infectious disease portfolio.

Beyond the preview

Go deeper on SBRX15.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBRX15.

Explore the full profile